ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 66 for:    Soft Tissue | "Dermatofibroma"

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01418001
Recruitment Status : Terminated (Lack of accrual)
First Posted : August 16, 2011
Results First Posted : February 17, 2016
Last Update Posted : January 11, 2018
Sponsor:
Collaborators:
National Comprehensive Cancer Network
University of California, Los Angeles
Washington University School of Medicine
Northwestern University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Sarcoma
Leiomyosarcoma
Malignant Peripheral Nerve Sheath Tumor
Malignant Fibrous
Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Intervention: Drug: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Pazopanib 400 mg QD Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib

Participant Flow:   Overall Study
    Pazopanib 400 mg QD
STARTED   5 
COMPLETED   5 
NOT COMPLETED   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Level 1: Pazopanib 400 mg QD Gemcitabine and Docetaxel in Com Level 1: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib

Baseline Measures
   Level 1: Pazopanib 400 mg QD Gemcitabine and Docetaxel in Com 
Overall Participants Analyzed 
[Units: Participants]
 5 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      1  20.0% 
>=65 years      4  80.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      1  20.0% 
Male      4  80.0% 


  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: Every 6 weeks up to 2 years ]

2.  Secondary:   Pathologic Response   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. William Tap
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-888-4163
e-mail: tapw@mskcc.org



Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01418001     History of Changes
Other Study ID Numbers: 11-104
First Submitted: August 15, 2011
First Posted: August 16, 2011
Results First Submitted: January 19, 2016
Results First Posted: February 17, 2016
Last Update Posted: January 11, 2018